The Proteome Has No Place To Hide.

Fast. Agnostic. First-in-class.

The Platform

Mercurious®

Most drug discovery starts with a known target and searches for a drug. Mercurious® inverts this entirely — starting with any bioactive compound and asking, with no prior assumptions, which proteins in the human proteome bind it. Phage-displayed cDNA libraries present the expressed human proteome as a biopannable surface, and iterative screening converges on the highest-affinity binding partners in days. Works equally on small molecules, biologics, and molecular glues. Reaches low-abundance proteins invisible to mass spectrometry. Returns primary target identification data in one to two weeks at a fraction of the cost of competing technologies.

AGNOSTIC

No prior target required. Works for any compound class — small molecules, biologics, or molecular glues.

ITERATIVE

Each biopanning round enriches genuine binders and removes noise, converging on real targets iteratively.

FAST

Primary target identification data in one to two weeks at a fraction of the cost of MS-based approaches.

Our Pipeline

Three Programmes. One Platform.

At MINIMUM bio we are focussed on building large libraries of rapamycin analogs (rapalogs) for three discovery pipelines in oncology, immunology and longevity.

These molecules are screened against phage-displayed libraries of human protein domains to rapidly and agnostically identify first-in-class targets in oncology and best-in-class rapalogs in immunology and longevity.

ONCOLOGY

undisclosed TF Glue

MB2052

●●○○○

Discovery/Validation

IMMUNOLOGY

Next-gen immunosuppressants

mTOR selective rapalogs

●○○○○

Discovery

LONGEVITY

Healthspan rapalgs

mTORC1 selective rapalogs

●○○○○

Discovery

Why Partner With Us

Unlock Value. Access the Undruggable.

At MINIMUM bio our expertise is in rapid and agnostic drug target identification for deconvolution of phenotypic screen, drug repositioning and off-target identification.

Another arm of the Mercurious platform is the generation of thousands to millions or rapamycin analogs, using FKBPs as chaperones to recruit clinically relevant hard-to-drug protein, unleashing the "undruggable" proteome.

→ UNBLOCK STALLED PIPELINES

Your Compound shows phenotypic activity but target identity is unclear? Mercurious resolves mechanism-of-action in days — turning pipeline risk into a developable candidate.

→ REACH UNDRUGGABLE TARGETS

FKBP-recruiting rapalogs form ternary complexes with transcription factors, protein-protein interfaces, and transmembrane proteins inaccessible to conventional small molecules.

→ ACCELERATE MOLECULAR GLUE PROGRAMS

Mercurious provides proteome-wide screening that DEL-based and rational design approaches cannot — identifying which structural variants recruit FKBP12 to which targets.

→ RAPALOG LIBRARY CO-DEVELOPMENT

Early partners gain preferred access to our growing FKBP12-recruiting compound library and co-invention rights on targets identified within agreed therapeutic areas.

The Team

Meet the Molecular Detectives.

At MINIMUM bio our team is 50% female, 80% PhDs.

We cover Chemistry, Molecular Biology, Pharmacology, Biophysics, PKS Engineering, Bioinformatics, Immunology, Deep Learning & Accounting/Finance

Peter Karuso PhD FRACI FRNS

CEO & Co-founder

PhD Chemistry · USyd · 15 yrs phage display · 2× founder

Adrian Keatinge-Clay PhD

CTO & Co-founder

PhD Chemistry · UCSF · PKS biosynthesis · UT Austin · 2× founder

Fei Liu PhD

CBDO & Co-founder

PhD Chemistry · Yale · Chemical proteomics & network pharmacology

Muralidhar Tata PhD

Chief Scientist

PhD mRNA Biology · Vienna · Library construction & protein expression

Vesna Lukic PhD

Director of AI & Operations

PhD Physics · Hamburg · Deep Learning, ML & Bioinformatics

Ramesh Bista PhD

PKS Engineer

PhD Biochemistry · UT Austin · Rapamycin PKS modules

Damaris Keatinge-Clay PhD

Immunology & Target Validation

PhD Immunology · U. Antioquia · Ex Molecular Templates

Pranita Poudyal PhD

Senior Scientist

PhD Microbiology · UNSW · Phage Biology

Sergueia Blas Chumacero BSc

Scientist

BSc (Hon.) Molecular Biotechnology · Chile · Phage Display & biopanning

Ryan Lee MPhil